ClinicalTrials.gg
RecruitingNCT06675955OleroMAXUpdated Oct 28, 2026

An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

A Phase 3 interventional study of Ocrelizumab in Multiple Sclerosis, sponsored by Hoffmann-La Roche. Recruiting at 56 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Oct 28, 2026First sites in Bulgaria and PeruSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.

Planned enrollment
7th of 27
500 · median 170
Started
2024
the only one that year
Phase 3
13 of 27
2 open now
Primary completion
2029-12
later than 12 of 13 live
Registered
24th of 27
by date
Lead sponsor
13 of 27
Hoffmann-La Roche

Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 7th largest by planned enrollment, is the only one that started in 2024, is one of 13 in phase 3, reaches primary completion later than 12 of the 13 other live ones, and was the 24th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ocrelizumab in Multiple Sclerosis, or all of them as a file.
02

Study summary

The study will evaluate the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab.

From Protocol Version 6 onwards, treatment within this study will be limited to the currently approved doses of ocrelizumab, 600 milligrams (mg), intravenous (IV) infusion or 920 mg, subcutaneous (SC) injection.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Ocrelizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who were on ongoing ocrelizumab treatment on one of the following parent-studies [Studies MN39159/CONSONANCE (NCT03523858), BN42082/MUSETTE (NCT04544436), BN42083/GAVOTTE (NCT04548999), BN44083/GLOBEAM, MN43978/CONSONANCE Ext., WA40404/O'HAND (NCT04035005), MN43964/OLERO (NCT05269004), GN41791/FENTREPID (NCT04544449), BP46016/MINTAKA, CN41144/OCARINA I-SC (NCT03972306), CN42097/OCARINA II-SC (NCT05232825)] at the time of roll-over and who do not have access to the ocrelizumab treatment locally
  • The first dose of study treatment in this extension study will be received no earlier than 5 months after the last treatment in the parent study
  • Negative urine pregnancy test within 24 hours to first dose administered on MN45053 study treatment in participants of

Exclusion criteria

Exclusion Criteria:

  • Study treatment is commercially marketed in the participant's country for the participant-specific disease and is reasonably accessible to the participant
  • Study treatment is available via Post Trial Access Program (PTAP) in the participant's country and is accessible to the participant
  • Permanent premature discontinuation of study treatment for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable)
  • Any condition that, in the opinion of the investigator, would interfere with the interpretation of participant safety or place the participant at high risk for treatment-related complications
  • Concurrent participation in any therapeutic clinical trial (other than the parent study)
  • state
  • Known active or are being actively monitored for recurrence of malignancy
  • Known presence of other neurological disorders
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Ocrelizumab

    Participants will receive ocrelizumab at the currently approved dose of 600 mg, IV infusion or 920 mg, SC injection as per the schedule in the parent study until access to the treatment becomes locally available, unacceptable safety concern, death or withdrawal of consent.

    Drug: Ocrelizumab

Interventions

  • Ocrelizumab will be administered at the approved dose of 600 mg, IV infusion or 920 mg, SC injection, according to the regimen in the parent study.

    Also known as: RO4964913; Ocrevus

06

What researchers measure

Primary outcomes

  1. Change From Baseline to End of Study in the Physical Functioning Score of the Patient-Reported Outcome Measure Information System/Quality of Life in Neurological Disorders - Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a)

    PROMISnq PFMS-15a includes 15 items that evaluate the impact of MS on a participant's physical functioning, including mobility, upper limb function and activities of daily living. Nine items assess the degree of difficulty in completing physical activities using a 5-point verbal rating scale ranging from 5="without any difficulty" to 1="unable to do". Four items assess physical function limitations, rated from 5="not at all" to 1="cannot do". Two items assess the amount of difficulty associated with selected physical activities, rated from 5="no difficulty" to 1="can't do". Scores are reported as a standardized T-score metric, with higher scores reflecting better physical functioning.

    Time frame: Baseline up to 5 years

  2. Number of Eligible Participants who Have Received Access to Ocrelizumab in the Study

    Time frame: Up to 5 years

Secondary outcomes

  1. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Up to 5 years

  2. Number of Participants With Adverse Events (AEs) Leading to Discontinuation

    Time frame: Up to 5 years

  3. Number of Participants With Adverse Events of Special Interest (AESIs)

    Time frame: Up to 5 years

07

Study locations

53 of 56 sites recruiting
  • MHAT Avis Medica OOD Department of Neurology
    Pleven, 5800, Bulgaria
    Recruiting
  • UMHAT 'Dr. Georgi Stranski', EAD
    Pleven, 5800, Bulgaria
    Recruiting
  • MHATNP Sveti Naum EAD
    Sofia, 1113, Bulgaria
    Recruiting
  • CHU Amiens Hopital Sud
    Amiens Cedex1, 80054, France
    Recruiting
  • CHIC Cote Basque Bayonne
    Bayonne, 64109, France
    Recruiting
  • CHU de Besancon Hopital Jean Minjoz
    Besançon, 25030, France
    Recruiting
  • Groupe Hospitalier Pellegrin
    Bordeaux, 33076, France
    Recruiting
  • CHU Brest Hopital La Cavale Blanche
    Brest, 29609, France
    Recruiting
  • Hopital neurologique Pierre Wertheimer - CHU Lyon
    Bron, 69677, France
    Recruiting
  • CHU De Caen
    Caen, 14033, France
    Recruiting
  • Hopital Gabriel Montpied CHU de Clermont-Ferrand
    Clermont-Ferrand, 63003, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • CH St Vincent de Paul
    Lille, 59000, France
    Recruiting
  • Hopital Roger Salengro Service de Neurologie
    Lille, DUMMY_VALUE, France
    Recruiting
  • Hopital Gui de Chauliac
    Montpellier, 34295, France
    Recruiting
  • Hopital Nord Laennec
    Nantes, 44093, France
    Recruiting
  • Hôpital Pasteur
    Nice, 06002, France
    Recruiting
  • GroupeHospitalo-Universitaire Caremeau
    Nîmes, 30029, France
    Recruiting
  • Centre Hospitalier Intercommunal de Poissy
    Poissy, 78300, France
    Recruiting
  • Hopital de Hautepierre
    Strasbourg, 67098, France
    Recruiting
  • Gesundheit Nord, Klinikum Bremen-Ost
    Bremen, 28325, Germany
    Recruiting
  • NeuroPoint Gesellschaft fur vorbeugende Gesundheitspflege mbH
    Ulm, 89073, Germany
    Recruiting
  • Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz
    Westerstede, 26655, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Deutsche Klinik für Diagnostik
    Wiesbaden, 65191, Germany
    Recruiting
  • Hospital IV Alberto Sabogal Sologuren
    Bellavista, Callao 2, Peru
    Recruiting
  • Hospital Nacional Guillermo Almenara Irigoyen
    La Victoria, Lima, Lima 13, Peru
    Recruiting
  • Hospital Nacional Dos de Mayo
    Lima, DUMMY_VALUE, Peru
    Recruiting
  • Instituto Nacional de Ciencias Neurológicas - Hospital Mogrovejo
    Lima, Lima 01, Peru
    Recruiting
  • Krasnoyarsk State Medical Academy
    Krasnoyarsk, Krasnoyarsk Krai 660022, Russia
    Recruiting
  • FSBHI Siberian Clinical Center of the Federal Medical and Biological Agency
    Krasnoyarsk, Krasnoyarsk Krai 660037, Russia
    Recruiting
  • Research Center of Neurology of RAMS
    Moscow, Moscow Oblast 125367, Russia
    Recruiting
  • City Clinical Hospital #24
    Moscow, Moscow Oblast 127015, Russia
    Recruiting
  • Federal center of brain research and neurotechnologies
    Moskva, Moscow Oblast 117997, Russia
    Recruiting
  • SBIH City Clinical Hospital #31
    Saint Petersburg, Sankt-Peterburg 197110, Russia
    Recruiting
  • LLC Osnova
    Saint Petersburg, Sankt-Peterburg 197341, Russia
    Recruiting
  • N.P. Bechtereva Institute of the Human Brain
    Saint Petersburg, Sankt-Peterburg 197376, Russia
    Recruiting
  • City Hospital #40 of Kurortniy Administrative District
    Saint Petersburg, Sankt-Peterburg 197706, Russia
    Recruiting
  • SHI Sverdlovsk Regional Clinical Hospital #1
    Yekaterinburg, Sverdlovsk Oblast 620102, Russia
    Recruiting
  • Vertebronevrologiya LLC
    Kazan', Tatarstan Republic 420043, Russia
    Recruiting
  • Ulyanovsk Regional Clinical Hospital
    Ulyanovsk, Ulyanovsk Oblast 432063, Russia
    Recruiting
  • Center of Cardiology and Neurology
    Kirov, 610007, Russia
    Recruiting
  • Regional clinical hospital named after prof. S.V. Ochapovsky
    Krasnodar, 350086, Russia
    Recruiting
  • FSBIH Siberian Regional Medical Centre of FMBA of Russia
    Novosibirsk, 630007, Russia
    Recruiting
  • Perm SMA n.a. academ. E.A. Vagner
    Perm, 614990, Russia
    Recruiting
  • 5th Cherkasy City Center of Primary Health Care
    Cherkasy, 18029, Ukraine
    Recruiting
  • Mun.Med.Proph.Inst.?Chernihiv Reg.Hosp.?
    Chernihiv, 14029, Ukraine
    Recruiting
  • Bukovinsky SMU RMI Chernivtsi RCH
    Chernivtsi, 58002, Ukraine
    Recruiting
  • SI USSRI of Medical and Social Problems of Disabilities of MOHU
    Dnipro, 49027, Ukraine
    Recruiting
  • Regional Clinical Hospital
    Ivano-Frankivsk, 76008, Ukraine
    Recruiting
  • St.In.Inst. of Neurol.Psych.and Narcol.of the AMSU
    Kharkiv, 61068, Ukraine
    Recruiting
  • Medical Center Dopomoga Plus
    Kyiv, 02123, Ukraine
    Recruiting
  • Medical Center of Private Execution First Private Clinic
    Kyiv, 03037, Ukraine
    Recruiting
  • Volyn Regional Clinical Hospital
    Lutsk, 43005, Ukraine
    Recruiting
  • Lvivska oblasna tsentralna likarnia
    Lviv, 79010, Ukraine
    Recruiting
  • Medical Clinical Research Center of Medical Center LLC Health Clinic
    Vinnytsi, 21009, Ukraine
    Recruiting
  • LCC "Medical center "Unimed"
    Zaporizhzhya, 69035, Ukraine
    Recruiting
  • Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council
    Zaporizhzhya, 69600, Ukraine
    Withdrawn

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2029, 60 months after the start.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 60 months is above that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 6, 2024
StartActual
Dec 13, 2024
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
13 sites added, 1 site removed — first sites in Bulgaria and Peru. 2 sites changed recruiting status (2 now withdrawn)
Show 2 sites
  • Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz · Westerstede, GermanyRecruiting→Withdrawn
  • Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council · Zaporizhzhya, UkraineRecruiting→Withdrawn
Show 13 added (4 Peru, 3 Bulgaria, 3 France, 2 Russia, 1 Germany)
  • MHAT Avis Medica OOD Department of Neurology · Pleven, Bulgaria
  • UMHAT 'Dr. Georgi Stranski', EAD · Pleven, Bulgaria
  • MHATNP Sveti Naum EAD · Sofia, Bulgaria
  • CHIC Cote Basque Bayonne · Bayonne, France
  • Hopital Roger Salengro Service de Neurologie · Lille, France
  • Centre Hospitalier Intercommunal de Poissy · Poissy, France
  • Gesundheit Nord, Klinikum Bremen-Ost · Bremen, Germany
  • Hospital IV Alberto Sabogal Sologuren · Bellavista, Peru
  • Hospital Nacional Guillermo Almenara Irigoyen · La Victoria, Lima, Peru
  • Hospital Nacional Dos de Mayo · Lima, Peru
  • Instituto Nacional de Ciencias Neurológicas - Hospital Mogrovejo · Lima, Peru
  • Research Center of Neurology of RAMS · Moscow, Russia
  • SBIH City Clinical Hospital #31 · Saint Petersburg, Russia
Show 1 removed
  • National Center of Social Significant Disease · Saint Petersburg, Russia
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    13 sites added, 1 site removed — first sites in Bulgaria and Peru. 2 sites changed recruiting status (2 now withdrawn)
    Show 2 sites
    • Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz · Westerstede, GermanyRecruiting→Withdrawn
    • Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council · Zaporizhzhya, UkraineRecruiting→Withdrawn
    Show 13 added (4 Peru, 3 Bulgaria, 3 France, 2 Russia, 1 Germany)
    • MHAT Avis Medica OOD Department of Neurology · Pleven, Bulgaria
    • UMHAT 'Dr. Georgi Stranski', EAD · Pleven, Bulgaria
    • MHATNP Sveti Naum EAD · Sofia, Bulgaria
    • CHIC Cote Basque Bayonne · Bayonne, France
    • Hopital Roger Salengro Service de Neurologie · Lille, France
    • Centre Hospitalier Intercommunal de Poissy · Poissy, France
    • Gesundheit Nord, Klinikum Bremen-Ost · Bremen, Germany
    • Hospital IV Alberto Sabogal Sologuren · Bellavista, Peru
    • Hospital Nacional Guillermo Almenara Irigoyen · La Victoria, Lima, Peru
    • Hospital Nacional Dos de Mayo · Lima, Peru
    • Instituto Nacional de Ciencias Neurológicas - Hospital Mogrovejo · Lima, Peru
    • Research Center of Neurology of RAMS · Moscow, Russia
    • SBIH City Clinical Hospital #31 · Saint Petersburg, Russia
    Show 1 removed
    • National Center of Social Significant Disease · Saint Petersburg, Russia
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06675955
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 6, 2024
Start date
Dec 13, 2024
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Reference Study ID Number: MN45053 https://forpatients.roche.com/
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion